The ImaginAb Team

Mr. Fractor has served as our Chief Financial Officer on a part-time basis since May 2019. Prior to joining ImaginAb, Mr. Fractor was the Chief Financial Officer at ImmunoCellular Therapeutics, Ltd. From 2011 to 2019, an NYSE American listed company developing cancer immunotherapies. While at ImmunoCellular Therapeutics, Mr. Fractor participated in numerous financial transactions and was responsible for meeting all SEC reporting requirements.  Since 2003, Mr. Fractor has been a consultant providing financial consulting and strategic planning services, to a variety of companies in various industries. From 1999 through 2003, Mr. Fractor was the Chief Financial Officer of HemaCare Corporation, a publicly traded corporation which collects, manufactures, tests and distributes blood products to hospitals and provides blood services to patients in hospital settings on an outsourcing basis. Mr. Fractor previously was an audit manager at Deloitte and received his B.S. in Accounting from the University of Southern California in 1982. He is a certified public accountant and a member of AICPA and the California Society of CPA’s.

Mr. Le joined ImaginAb to lead the clinical development effort that includes Clinical Operations, Program and Project Management, CMC, Quality and Strategic Alliance Management. Mr. Le has 17+ years of industry experience in clinical research and cross-functional leadership in biotechnology and pharmaceutical drug development from Phase I–IV. Prior to joining ImaginAb, Mr. Le has held senior leadership role at Gradalis Inc., a start-up biotechnology company developing personalized molecular-based immuno-oncology therapies, functioning in a similar leadership role and capacity; and at Spectrum Pharmaceuticals where he managed and completed two registration programs that were submitted for New Drug Application (NDA), resulting in one being approved for the treatment of a rare disease. Mr. Le also spent years working at the major CRO’s before joining the industry Sponsor. Mr. Le obtained his Bachelor’s degree in Management from Oklahoma State University and his Master’s degree in Biotechnology Management from the University of Maryland University College.